# Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

> **NCT02538627** · PHASE1 · TERMINATED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Colorectal Cancer
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** MM-151
- **DRUG:** MM-121
- **DRUG:** MM-141
- **DRUG:** trametinib

## Key facts

- **NCT ID:** NCT02538627
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2016-10-05
- **Final completion:** 2016-10-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538627, "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02538627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*